Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
3179.00    95.00 (3.08%)
Bid:
3186.00
Ask:
3188.00
Spread: 2.00 (0.063%)
Market Cap: £4.43b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

Acquisition

24 May 2013 07:00

RNS Number : 4809F
Croda International PLC
24 May 2013
 



24 May 2013

 

Croda International Plc

 

Acquisition ofSpecialty Products Business from Arizona Chemical

Naturally derived polyamides expand Croda's broad portfolio of effects

 

Croda International Plc announces today that it has completed the acquisition of the Specialty Products business of Arizona Chemical based in Jacksonville, Florida in the USA. 

 

The acquisition adds a portfolio of class leading oil gelling polymers to Croda's business and further expands its footprint in the polymers arena, while strengthening Croda's leading position in speciality chemicals derived from renewable resources. The technologies and products of the acquired business are naturally derived polyamides with high bio-renewable content, covered by a range of patents.

 

Keith Layden, Croda's Chief Technology Officer, said:

 

"This acquisition represents further progress in our strategy to acquire complementary new technologies. The varied functionality of these specialised polyamides will be a valuable addition to our offerings across both the Consumer Care and Performance Technologies market sectors. In addition, there are a number of opportunities to further differentiate the technology and create value for ourselves and our customers."

 

No manufacturing assets will be acquired as part of this transaction and Croda will immediately commence the relocation of the products to Croda's Mevisa manufacturing site in Spain and when ready, re-launch the products with new trade names and marketing identities.

 

For further information please contact:

 

Keith Layden, Chief Technology Officer Tel: 01405 860 551

Sean Christie, Group Finance Director

 

Charles Armitstead / Rosie Oddy, Pendomer Communications Tel: 020 3603 5224 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQAJMATMBJTBFJ
Date   Source Headline
1st Nov 20241:44 pmRNSHolding(s) in Company
11th Oct 20242:13 pmRNSDirector/PDMR Shareholding
10th Oct 20243:39 pmRNSDirector/PDMR Shareholding
13th Sep 202410:07 amRNSDirector/PDMR Shareholding
11th Sep 20242:52 pmRNSDirector/PDMR Shareholding
13th Aug 20241:51 pmRNSDirector/PDMR Shareholding
30th Jul 20241:49 pmRNSDirector/PDMR Shareholding - Replacement
30th Jul 20241:40 pmRNSDirector/PDMR Shareholding
30th Jul 20247:00 amRNSResults for the six months ended 30 June 2024
12th Jul 202411:10 amRNSDirector Declaration
11th Jul 20242:21 pmRNSDirector/PDMR Shareholding
1st Jul 20247:00 amRNSCroda appoints Chief Financial Officer
25th Jun 202410:00 amRNSDirector/PDMR Shareholding
25th Jun 20247:00 amRNSDirectorate Change
13th Jun 20249:46 amRNSHolding(s) in Company
12th Jun 20249:01 amRNSDirector/PDMR Shareholding
11th Jun 20242:12 pmRNSDirector/PDMR Shareholding
30th May 20243:27 pmRNSDirector/PDMR Shareholding
30th May 20242:33 pmRNSDirector/PDMR Shareholding
13th May 20242:16 pmRNSDirector/PDMR Shareholding
2nd May 20249:27 amRNSDirector/PDMR Shareholding
1st May 202412:18 pmRNSDirector/PDMR Shareholding
25th Apr 202410:01 amRNSResult of AGM
24th Apr 20247:00 amRNSFirst quarter 2024 sales update
11th Apr 20242:11 pmRNSDirector/PDMR Shareholding
8th Apr 202410:54 amRNSDirector/PDMR Shareholding
8th Apr 202410:23 amRNSDirector/PDMR Shareholding
28th Mar 20249:17 amRNSDirector/PDMR Shareholding
26th Mar 20244:19 pmRNSDirector/PDMR Shareholding
26th Mar 20244:10 pmRNSDirector/PDMR Shareholding
26th Mar 20244:09 pmRNSDirector/PDMR Shareholding
26th Mar 20244:09 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSDirector/PDMR Shareholding
26th Mar 20244:06 pmRNSDirector/PDMR Shareholding
26th Mar 20244:04 pmRNSDirector/PDMR Shareholding
15th Mar 20249:32 amRNSAnnual Financial Report
12th Mar 20242:49 pmRNSDirector/PDMR Shareholding
7th Mar 20243:03 pmRNSDirector/PDMR Shareholding
27th Feb 20247:00 amRNSResults for the year ended 31 December 2023
13th Feb 20243:35 pmRNSDirector/PDMR Shareholding
9th Feb 20243:28 pmRNSHolding(s) in Company
18th Jan 20241:33 pmRNSHolding(s) in Company
11th Jan 20243:17 pmRNSDirector/PDMR Shareholding
18th Dec 20237:00 amRNSDirectorate Change
12th Dec 20233:08 pmRNSDirector/PDMR Shareholding
11th Dec 202311:39 amRNSDirector Declaration
29th Nov 20234:54 pmRNSHolding(s) in Company
28th Nov 20239:35 amRNSDirector/PDMR Shareholding
24th Nov 202311:33 amRNSHolding(s) in Company
14th Nov 20239:40 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.